Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Lucidarme

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Vaccine|March 23, 2020
Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017Mehmet Ceyhan, Yasemin Ozsurekci, Jay Lucidarme, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 17, 2019
Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody AssaysJay Lucidarme, Jennifer Louth, Kelly Townsend-Payne, et al.
Plos One|March 4, 2014
Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimensStephen A Clark, Jay Lucidarme, Lynne S Newbold, et al.
Expert Review of Vaccines|July 21, 2021
Correlates of protection for meningococcal surface protein vaccines: lessons from the pastJamie Findlow, Jay Lucidarme, Muhamed-Kheir Taha, et al.
International Journal of Medical Microbiology : IJMM|November 21, 2017
Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimensStephen A Clark, Ronan Doyle, Jay Lucidarme, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 18, 2015
Meningococcal vaccine antigen diversity in global databasesCarina Brehony, Dorothea M Hill, Jay Lucidarme, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding proteinJay Lucidarme, Lionel Tan, Rachel M Exley, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 10, 2019
Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16Helen Findlow, Helen Campbell, Jay Lucidarme, et al.
Vaccine|February 12, 2022
Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in EnglandShamez N Ladhani, Helen Campbell, Zahin Amin-Chowdhury, et al.
Lancet (London, England)|June 15, 2020
Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidisShamez N Ladhani, Jay Lucidarme, Sydel R Parikh, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Vaccine|March 23, 2020
Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017Mehmet Ceyhan, Yasemin Ozsurekci, Jay Lucidarme, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 17, 2019
Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody AssaysJay Lucidarme, Jennifer Louth, Kelly Townsend-Payne, et al.
Plos One|March 4, 2014
Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimensStephen A Clark, Jay Lucidarme, Lynne S Newbold, et al.
Expert Review of Vaccines|July 21, 2021
Correlates of protection for meningococcal surface protein vaccines: lessons from the pastJamie Findlow, Jay Lucidarme, Muhamed-Kheir Taha, et al.
International Journal of Medical Microbiology : IJMM|November 21, 2017
Targeted DNA enrichment and whole genome sequencing of Neisseria meningitidis directly from clinical specimensStephen A Clark, Ronan Doyle, Jay Lucidarme, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 18, 2015
Meningococcal vaccine antigen diversity in global databasesCarina Brehony, Dorothea M Hill, Jay Lucidarme, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding proteinJay Lucidarme, Lionel Tan, Rachel M Exley, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 10, 2019
Serogroup C <i>Neisseria meningitidis</i> disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16Helen Findlow, Helen Campbell, Jay Lucidarme, et al.
Vaccine|February 12, 2022
Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in EnglandShamez N Ladhani, Helen Campbell, Zahin Amin-Chowdhury, et al.
Lancet (London, England)|June 15, 2020
Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidisShamez N Ladhani, Jay Lucidarme, Sydel R Parikh, et al.
Pageof 9